Clinical trials: Immunosuppressive Treatment
Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.
- Conditions
- Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04305444
- Testing
- DTRM-555
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Zhejiang DTRM Biopharma
Crohn, Ulcerative Colitis (UC)
Research and Follow-up of the Determinants of the Progression and Complications of Inflammatory Bowel Diseases Treated or Not With Immunosuppressants.
Inflammatory Bowel Diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic, disabling conditions affecting young adults, marked by flare-ups and remissions.
- Conditions
- Crohn, Ulcerative Colitis (UC), IBD (Inflammatory Bowel Disease)
- Trial name
- SUIVITHEQUE2 (NCT07172945)
- Testing
- Blood, fecal, saliva, intestinal content samples and biopsies
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lung Disease, Interstitial
Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases
The purpose of the study is to evaluate the efficacy on lung function 6 months after one course of rituximab (2 infusions) and mycophénolate mofétil (MMF) treatment compared to one course of placebo and 6 months of MMF treatment…
- Trial name
- EvER-ILD (NCT02990286)
- Testing
- Rituximab, Mycophenolate Mofetil
- Where
- 5 sites in France
- Volunteers
- 122 people
- Sponsor
- University Hospital, Tours
Solid Organ Transplant Rejection, Organ Rejection Transplants
Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients
This Expanded Access Protocol will provide access to the IMP ExoFlo for patients who have severe or life-threatening abdominal solid organ transplant rejection or who are evaluated and determined to be at high risk of progression…
- Conditions
- Solid Organ Transplant Rejection, Organ Rejection Transplants, Organ Rejection
- Trial name
- NCT05215288
- Testing
- ExoFlo
- Where
- 2 sites in United States
- Sponsor
- Direct Biologics, LLC
Severe Aplastic Anemia
Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy
Background: People with severe aplastic anemia (SAA) do not make enough red and white blood cells, and/or platelets. Their body's immune system stops the bone marrow from making these cells.
- Trial name
- NCT02979873
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Diabetes Mellitus, Type 1
New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial
The objective of this study is to identify immune intervention strategies that will preserve residual beta cell function at the onset of type 1 diabetes.
- Trial name
- TN02 (NCT00100178)
- Testing
- Mycophenolate mofeteil (MMF), Daclizumab (DZB)
- Where
- 11 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Aplastic Anemia
Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects
This was an open label, non-randomized, phase II study of eltrombopag in combination with rabbit ATG/CsA in subjects with moderate or more severe AA who did not received prior ATG/ALG-based immunosuppressive therapy.
- Trial name
- NCT02404025
- Testing
- Eltrombopag, Rabbit ATG, CsA
- Where
- 11 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, End Stage Renal Disease
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
This prospective randomized trial aims to evaluate the feasibility, risk and benefit of the discontinuation of immunosuppressive maintenance treatments in AAV (Antineutrophil Cytoplasmic Autoantibodies (ANCA)-associated…
- Trial name
- MASTER-ANCA (NCT03323476)
- Testing
- Discontinuation (or not initiation) of Immunosuppressive Therapy, Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
- Where
- 57 sites in France
- Volunteers
- 136 people
- Sponsor
- Centre Hospitalier Departemental Vendee
Kidney Transplantation, Medication Non-Adherence
Kidney Transplant Immunosuppressive Therapy Adherence Trial (KITE)
This randomized controlled interventional study aims to evaluate the effect of structured education and telephone counseling on immunosuppressive medication adherence among kidney transplant recipients.
- Conditions
- Kidney Transplantation, Medication Non-Adherence, Immunosuppressive Therapy, Renal Transplant Recipients
- Trial name
- KITE (NCT07364123)
- Testing
- Education and Telephone Counseling Program
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- University of Gaziantep
Dilated Cardiomyopathy (DCM), Heart Failure
Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
To study the safety and efficacy of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of end-stage dilated cardiomyopathy and provide a new method…
- Trial name
- NCT06902896
- Testing
- FAP immunosuppressive CAR-DC
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer, Chronic Myeloproliferative Disorders
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00010283
- Testing
- beclomethasone dipropionate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Ulcerative Colitis, Active Moderate
Adacolumn in Refractory UC Patients Trial
The objectives of the study are to observe and document the efficacy and safety of 5 or more Adacolumn treatments, administered once weekly over 5 or more weeks, in a specific subset of ulcerative colitis patients.
- Trial name
- ART (NCT01481142)
- Testing
- (GMA) Adsorptive Apheresis
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Kidney Transplantation
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
Nonadherence to immunosuppression is a leading cause of late graft rejection, chronic rejection and graft failure and it is regarded as a preventable cause of graft loss after solid organ transplantation.
- Trial name
- PRIMA (NCT01905514)
- Testing
- internet mobile application
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- Seoul National University Hospital
Hematopoietic Cell Transplant
The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow Transplant Patients
The goal of this clinical trial is to test the MedMemos Intervention with parents and children who have received a bone marrow transplant.
- Trial name
- MedMemos (NCT07718204)
- Testing
- MedMemos
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Nationwide Children's Hospital
Liver Transplantation
REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy
The purpose of this study was, starting from the Italian clinical practice in liver transplantation, to optimize the immunosuppressive therapy, considering specific patient characteristics as alcoholic cirrhosis, hepatitis C…
- Trial name
- REFLECT (NCT02115113)
- Testing
- Everolimus, Tacrolimus
- Where
- 14 sites in Italy
- Volunteers
- 78 people
- Sponsor
- Novartis Pharmaceuticals
Severe Aplastic Anemia (SAA)
Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy
Romiplostim has been used in clinical trials for the treatment of severe and very severe aplastic anemia (SAA/vSAA) in Asian participants who are either previously untreated with immunosuppressive therapy (IST) or refractory to…
- Trial name
- NCT05323617
- Testing
- Romiplostim, Antithymocyte Globulin, Cyclosporine A
- Sponsor
- Amgen
Sarcoidosis
Use of Immunosuppressive Therapy for Sarcoidosis
Retrospective review of the outcome of use of immunosuppressive drugs in treatment of sarcoidosis
- Trial name
- NCT02356445
- Testing
- Cytotoxic drug
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- University of Cincinnati
Pharmacokinetics, Area Under Curve
Model Informed preciSion doSIng tO iNdividualise and Optimize Pharmacotherapeutic Treatment
This is a prospective observational study of MIPD in clinical practice for paediatric kidney transplant patients using tacrolimus and mycophenolic acid in Radboudumc.
- Conditions
- Pharmacokinetics, Area Under Curve, Tacrolimus, Immunosuppressive Agents
- Trial name
- MISSION (NCT06095895)
- Testing
- venipuncture
- Where
- Netherlands
- Volunteers
- 29 people
- Sponsor
- Radboud University Medical Center
Kidney Transplant Rejection, Medication Adherence
Immunosuppressant Medication Dosed Daily After Kidney Transplant
Medication non-adherence is a major risk factor for graft dysfunction and graft loss among pediatric and adult transplant recipients.
- Trial name
- NCT04156204
- Testing
- Medication Event Monitoring System (MEMS), Once-Daily Tacrolimus extended release
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Colorado, Denver
Lung Trasplant, Lung Transplantation
Study of Tacrolimus Melt-Dose® for Lung Transplant Patients
To evaluate, under usual clinical practice conditions and with a 12-month follow-up , the most relevant pharmacokinetic parameters of tacrolimus metabolism and safety, in patients with recent lung transplant (unilateral or…
- Trial name
- ESENCIAL (NCT07042035)
- Where
- 2 sites in Spain
- Volunteers
- 240 people
- Sponsor
- Chiesi España, S.A.U.